176 related articles for article (PubMed ID: 18571285)
21. Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease.
Wright JA; Brown DR
J Neurosci Res; 2008 Feb; 86(3):496-503. PubMed ID: 17705291
[TBL] [Abstract][Full Text] [Related]
22. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
24. Structural characterization of the intrinsically unfolded protein beta-synuclein, a natural negative regulator of alpha-synuclein aggregation.
Bertoncini CW; Rasia RM; Lamberto GR; Binolfi A; Zweckstetter M; Griesinger C; Fernandez CO
J Mol Biol; 2007 Sep; 372(3):708-22. PubMed ID: 17681539
[TBL] [Abstract][Full Text] [Related]
25. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
26. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
28. Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment.
Kim HJ; Chatani E; Goto Y; Paik SR
J Microbiol Biotechnol; 2007 Dec; 17(12):2027-32. PubMed ID: 18167451
[TBL] [Abstract][Full Text] [Related]
29. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers.
Näsström T; Wahlberg T; Karlsson M; Nikolajeff F; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2009 Jan; 378(4):872-6. PubMed ID: 19070597
[TBL] [Abstract][Full Text] [Related]
30. Double-stranded DNA stimulates the fibrillation of alpha-synuclein in vitro and is associated with the mature fibrils: an electron microscopy study.
Cherny D; Hoyer W; Subramaniam V; Jovin TM
J Mol Biol; 2004 Dec; 344(4):929-38. PubMed ID: 15544803
[TBL] [Abstract][Full Text] [Related]
31. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein.
Rekas A; Lo V; Gadd GE; Cappai R; Yun SI
Macromol Biosci; 2009 Mar; 9(3):230-8. PubMed ID: 19116892
[TBL] [Abstract][Full Text] [Related]
32. Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation.
Ferreon AC; Deniz AA
Biochemistry; 2007 Apr; 46(15):4499-509. PubMed ID: 17378587
[TBL] [Abstract][Full Text] [Related]
33. Acceleration of alpha-synuclein aggregation by homologous peptides.
Du HN; Li HT; Zhang F; Lin XJ; Shi JH; Shi YH; Ji LN; Hu J; Lin DH; Hu HY
FEBS Lett; 2006 Jun; 580(15):3657-64. PubMed ID: 16764865
[TBL] [Abstract][Full Text] [Related]
34. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
[TBL] [Abstract][Full Text] [Related]
35. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation.
Binolfi A; Lamberto GR; Duran R; Quintanar L; Bertoncini CW; Souza JM; Cerveñansky C; Zweckstetter M; Griesinger C; Fernández CO
J Am Chem Soc; 2008 Sep; 130(35):11801-12. PubMed ID: 18693689
[TBL] [Abstract][Full Text] [Related]
36. Macromolecular crowding in the Escherichia coli periplasm maintains alpha-synuclein disorder.
McNulty BC; Young GB; Pielak GJ
J Mol Biol; 2006 Feb; 355(5):893-7. PubMed ID: 16343531
[TBL] [Abstract][Full Text] [Related]
37. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
[TBL] [Abstract][Full Text] [Related]
38. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric fluorescence detection of early stages in the amyloid protein aggregation of pyrene-labeled alpha-synuclein.
Thirunavukkuarasu S; Jares-Erijman EA; Jovin TM
J Mol Biol; 2008 May; 378(5):1064-73. PubMed ID: 18433772
[TBL] [Abstract][Full Text] [Related]
40. DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes.
Hegde ML; Rao KS
Arch Biochem Biophys; 2007 Aug; 464(1):57-69. PubMed ID: 17537399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
